News Conference News ESC 2025 ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD L.A. McKeown September 09, 2025
News Opinion Editor's Corner ESC 2025 What’s Going to Be Hot at ESC Congress 2025? Michael O'Riordan August 25, 2025
News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients Michael O'Riordan September 01, 2024
News Conference News ESC 2024 HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM L.A. McKeown August 30, 2024
News Conference News ESC 2023 More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM Michael O'Riordan August 31, 2023
News Conference News ESC 2023 STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function Shelley Wood August 25, 2023
News Opinion Editor's Corner ESC 2023 What’s Going to Be Hot at ESC 2023? Shelley Wood August 15, 2023
News Conference News ESC 2022 PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2 Michael O'Riordan August 27, 2022
News Conference News ESC 2018 My Takeaways From ESC 2018: Good or Bad, the Luxury of New Data Begets Cries for More Shelley Wood September 14, 2018
News Conference News ESC 2018 Tafamidis, a Transthyretin Stabilizer, Offers Hope for Rare Cardiomyopathy Michael O'Riordan August 27, 2018
News Conference News ESC 2016 ICDs Do Not Reduce Mortality in Patients With HF Not Caused by Coronary Artery Disease: DANISH Michael O'Riordan August 28, 2016